Role and place of dulaglutide in type 2 diabetes mellitus management
AbstractDestructive macro- and microvascular complications of diabetes mellitus lead to an increase of mortality, loss of vision, kidney failure and a an overalldecrease in quality of life. The appearance of GLP-1 receptor agonists (GLP-1 RAs) has become a breakthrough in the treatment of patients with type 2 diabetes. The multidirectional pleiotropic effects of GLP-1 RAs make it possible to classify them as disease-modifying drugs in the treatment of type 2 diabetes. Dulaglutide is an effective and easy-to-use hypoglycemic drug that leads to a pronounced and sustained weight loss and has a cardioprotective effect, contributing to both secondary and primary prevention of cardiovascular diseases.
Keywords:type 2 diabetes mellitus; dulaglutide; antidiabetic effect; cardioprotective effect; ease of use; patient profile
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. Thematic publications reviewing, writing of the article, data processing, analysis and interpretation, approval of the manuscript for publication – Ametov A.S., Pyanykh O.P.; writing the text and design of the article, thematic publications reviewing – Antsiferova D.M.
For citation: Ametov A.S., Antsiferova D.M., Pyanykh O.P. Role and place of dulaglutide in type 2 diabetes mellitus management. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (4): 72–7. DOI: https://doi.org/10.33029/2304-9529-2023-12-4-72-77 (in Russian)
References
1. International Diabetes Federation (IDF). IDF Diabetes Atlas. 10th ed. 2021. URL: https://diabetesatlas.org/ (date of access December 6, 2022).
2. da Rocha Fernandes J., Ogurtsova K., Linnenkamp U., et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016; 117: 48–54. DOI: https://doi.org/10.1016/J.DIABRES.2016.04.016
3. Yang W., Dall T.M., Beronjia K., et al. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018; 41 (5): 917–28. DOI: https://doi.org/10.2337/DCI18-0007/-/DC1
4. Liyanage T., Ninomiya T., Jha V., et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385 (9981): 1975–82. DOI: https://doi.org/10.1016/S0140-6736(14)61601-9
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414 (6865): 813–20. DOI: https://doi.org/10.1038/414813A
6. Cole J.B., Florez J.C. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020; 16 (7): 377–90. DOI: https://doi.org/10.1038/S41581-020-0278-5
7. Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58 (4): 773–95. DOI: https://doi.org/10.2337/DB 09-9028
8. Rodriguez-Gutierrez R., Gionfriddo M.R., Ospina N.S., et al. Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol. 2016; 4 (8): 706–16. DOI: https://doi.org/10.1016/S2213-8587(15)00468-4
9. Ferrannini E., DeFronzo R.A. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015; 36 (34): 2288–96. DOI: https://doi.org/10.1093/EURHEARTJ/EHV239
10. Morrish N.J., Wang S.L., Stevens L.K., et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44 (suppl 2): S 14–21. DOI: https://doi.org/10.1007/PL00002934
11. Sun S., Hisland L., Grenet G., et al. Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control-trials. Therapie. 2022; 77 (4): 413–23. DOI: https://doi.org/10.1016/J.THERAP.2021.10.002
12. Agrawal L., Azad N., Bahn G.D., et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2018; 61 (2): 295–9. DOI: https://doi.org/10.1007/S00125-017-4473-2
13. Lind M., Imberg H., Coleman R.L., et al. Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021; 44 (10): 2231–7. DOI: https://doi.org/10.2337/DC 20-2439
14. Zelniker T.A., Wiviott S.D., Raz I., et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139 (17): 2022–31. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.038868
15. Mahaffey K.W., Jardine M.J., Bompoint S., et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019; 140 (9): 739–50. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.042007
16. Perkovic V., Jardine M.J., Neal B., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380 (24): 2295–306. DOI: https://doi.org/10.1056/NEJMOA1811744
17. Davies M.J., Aroda V.R., Collins B.S., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022; 65 (12): 1925–66. DOI: https://doi.org/10.1007/S00125-022-05787-2
18. Davies M.J., D’Alessio D.A., Fradkin J., et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61 (12): 2461–98. DOI: https://doi.org/10.1007/S 00125-018-4729-5
19. Buse J.B., Wexler D.J., Tsapas A., et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020; 63 (2): 221–8. DOI: https://doi.org/10.1007/S00125-019-05039-W
20. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021; 46: 101102. DOI: https://doi.org/10.1016/J.MOLMET.2020.101102
21. Gallwitz B., Dagogo-Jack S., Thieu V., et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018; 20 (2): 409–18. DOI: https://doi.org/10.1111/DOM.13086
22. Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394 (10 193): 121–30. DOI: https://doi.org/10.1016/S0140-6736(19)31149-3
23. Umpierrez G., Povedano S.T., Manghi F.P., et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014; 37 (8): 2168–76. DOI: https://doi.org/10.2337/DC 13-2759
24. Nauck M., Weinstock R.S., Umpierrez G.E., et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014; 37 (8): 2149–58. DOI: https://doi.org/10.2337/DC 13-2761
25. Dungan K.M., Povedano S.T., Forst T., et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384 (9951): 1349–57. DOI: https://doi.org/10.1016/S0140-6736(14)60976-4
26. Wysham C., Blevins T., Arakaki R., et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014; 37 (8): 2159–67. DOI: https://doi.org/10.2337/DC13-2760
27. Giorgino F., Benroubi M., Sun J.H., et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015; 38 (12): 2241–9. DOI: https://doi.org/10.2337/DC14-1625
28. Jendle J., Rosenstock J., Blonde L., et al. Better glycemic control and less weight gain with once weekly dulaglutide vs once daily insulin glargine, both combined with pre-meal insulin lispro, in type 2 diabetes patients (AWARD-4). Can J Diabetes. 2014; 38 (5): S 50. DOI: https://doi.org/10.1016/j.jcjd.2014.07.136
29. Pozzilli P., Norwood P., Jódar E., et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017; 19 (7): 1024–31. DOI: https://doi.org/10.1111/DOM.12937
30. Dungan K.M., Weitgasser R., Perez Manghi F., et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016; 18 (5): 475–82. DOI: https://doi.org/10.1111/DOM.12634
31. Tuttle K.R., Lakshmanan M.C., Rayner B., Zimmermann A.G., Woodward B., Botros F.T. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Diabetes Obes Metab. 2019; 21 (6): 1493–7. DOI: https://doi.org/10.1111/DOM.13668
32. Ludvik B., Frías J.P., Tinahones F.J., et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018; 6 (5): 370–81. DOI: https://doi.org/10.1016/S2213-8587(18)30023-8
33. Weinstock R.S., Guerci B., Umpierrez G., et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015; 17 (9): 849–58. DOI: https://doi.org/10.1111/DOM.12479
34. Robinson S., Boye K.S., Mody R., et al. Real-world effectiveness of dulaglutide in patients with type 2 diabetes mellitus: a literature review. Diabetes Ther. 2020; 11 (7): 1437–66. DOI: https://doi.org/10.1007/S 13300-020-00839-5
35. Atkinson R., Bharaj J., Basu A., et al. Efficacy or convenience: which should we consider for glucagon-like peptide (GLP)-1 analogue therapy? Diab Med. 2018; 35 (suppl 1): 70.
36. Maccora C., Formichi C., Crisci I., et al. Efficacy of liraglutide, dulaglutide and SGLT2 inhibitors in obese/overweight patients with type 2 diabetes mellitus. Obes Facts. 2019; 12 (suppl 1): 71.
37. Kang W.H., Rohana J., Norasyikin A.W., et al. Weight loss and A1c reduction: our experience with dulaglutide. J Diabetes Investig. 2018; 9 (suppl 1): 132.
38. International Diabetes Federation (IDF). IDF Diabetes Atlas 7th ed. 2015.
39. Abraham T.M., Pencina K.M., Pencina M.J., et al. Trends in diabetes incidence: the Framingham Heart Study. Diabetes Care. 2015; 38 (3): 482–7. DOI: https://doi.org/10.2337/DC 14-1432
40. International Diabetes Federation. Diabetes and cardiovascular disease. Brussels: International Diabetes Federation, 2016: 1–144.
41. Sarwar N., Gao P., Kondapally Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375 (9733): 2215–22. DOI: https://doi.org/10.1016/S0140-6736(10)60484-9
42. Singh G.M., Danaei G., Farzadfar F., et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013; 8 (7): e65174. DOI: https://doi.org/10.1371/JOURNAL.PONE.0065174
43. Einarson T.R., Acs A., Ludwig C., et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018; 17 (1): 83. DOI: https://doi.org/10.1186/S 12933-018-0728-6
44. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019; 42 (suppl 1): S 103–23. DOI: https://doi.org/10.2337/DC19-S010
45. Ferrannini G., Mellbin L.G., Kirabo F., et al. Dulaglutide and a composite outcome reflecting atherosclerosis in the REWIND trial: a post hoc analysis. Diabetes Care. 2022; 45 (10): e146–e147. DOI: https://doi.org/10.2337/DC22-0903
46. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. Москва, 2023. [Algorithms of specialized medical care for patients with diabetes mellitus. In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). 11th issue. Moscow, 2023: 1–236. DOI: https://doi.org/10.14341/DM13042 (in Russian)]
47. Blonde L., Jendle J., Gross J., et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015; 385 (9982): 2057–66. DOI: https://doi.org/10.1016/S0140-6736(15)60936-9
48. Tuttle K.R., Lakshmanan M.C., Rayner B., et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018; 6 (8): 605–17. DOI: https://doi.org/10.1016/S2213-8587(18)30104-9
49. Peyrot M., Matthews D., Snoek F., et al. An international study of psychological resistance to insulin use among persons with diabetes. Diabetologia. 2003; 46 (suppl 2): A89.
50. Peyrot M., Rubin R.R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28 (11): 2673–9. DOI: https://doi.org/10.2337/DIACARE.28.11.2673
51. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26 (suppl 3): S 18–24. DOI: https://doi.org/10.1038/SJ.IJO.0802173
52. An J., Nichol M.B. Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension. Med Care. 2013; 51 (10): 879–87. DOI: https://doi.org/10.1097/MLR.0B013E31829FA8ED
53. Hornsten A., Lundman B., Selstam E.K., et al. Patient satisfaction with diabetes care. J Adv Nurs. 2005; 51 (6): 609–17. DOI: https://doi.org/10.1111/J.1365-2648.2005.03546.X
54. Fu A.Z., Qiu Y., Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin. 2009; 25 (6): 1413–20. DOI: https://doi.org/10.1185/03007990902905724
55. Matfin G., Van Brunt K., Zimmermann A.G., et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol. 2015; 9 (5): 1071–9. DOI: https://doi.org/10.1177/1932296815583059
56. Matza L.S., Boye K.S., Stewart K.D., et al. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: a crossover study (PREFER). Diabetes Obes Metab. 2020; 22 (3): 355–64. DOI: https://doi.org/10.1111/DOM.13902